GLP-1Jun 4, 2026
In the trial that got Zepbound approved, the average person on the highest 15 mg dose lost 20.9% of their body weight over 72 weeks. The 10 mg dose was 19.5%, and the 5 mg dose was 15.0%. The highest dose wins on paper, but only by 1.4 percentage points over 10 mg, while gastrointestinal side effects keep rising and discontinuation creeps up.
If you're thinking about Zepbound, the more useful question isn't which dose produces the absolute most weight loss in a trial. It's which dose produces the most weight loss YOU can actually stay on for a year or longer. Those answers can differ.
GLP-1Jun 4, 2026
In a trial of 27,564 patients followed for over two years, evolocumab (Repatha) cut LDL cholesterol by 59% and lowered major cardiovascular events by 15%, with no meaningful difference in adverse events versus placebo aside from a small uptick in injection-site reactions. Weight loss was not on the list of effects, then or in any subsequent analysis.
If you have heard that an injectable drug helps with weight, you are probably thinking of a different class. Wegovy, Zepbound, Ozempic, and Mounjaro are GLP-1 receptor agonists, designed specifically to drive weight loss. Repatha was designed for cholesterol.
They are all injections, administered weekly or monthly, and all expensive. They do not do the same thing.
GLP-1Jun 4, 2026
Zepbound's pen authorizes three injection sites (abdomen, thigh, and upper arm), and pharmacokinetic data show the drug absorbs about the same regardless of which one you use. The catch is what happens to the skin underneath after weeks of injecting in roughly the same place: a fibrofatty thickening called lipohypertrophy, which affects up to 60% of long-term self-injecting diabetes patients.
If you're holding your first Zepbound pen and wondering which site to use, the answer is: any of the three. The bigger question is what you'll do over the months that follow. Where you keep returning the needle, more than where you start, decides whether the medication still absorbs as expected after dozens of doses.
GLP-1Jun 4, 2026
In the landmark trial that got Zepbound approved, the average person on the 15 mg dose lost 20.9% of their starting body weight over 72 weeks. That number gets quoted constantly in marketing copy, but it hides three things every prospective patient should know: results depend heavily on dose, real-world losses tend to be smaller, and the weight comes back fast if you stop the drug.
This is what tens of thousands of patients across clinical trials and real-world studies tell us about what to actually expect.
Weight LossJun 4, 2026
If you're considering prescription weight loss medication, you've probably heard of Zepbound and Wegovy. Both are weekly injections that produce significant weight loss, but one consistently outperforms the other on the scale. The tradeoff? The drug that helps you lose more weight doesn't yet have the same proof that it'll protect your heart.
Here's the bottom line from clinical trials: Zepbound typically produces about 5-7 percentage points more weight loss than Wegovy over a year to 18 months. But Wegovy has years of rigorous data showing it reduces heart attacks, strokes, and cardiovascular deaths. Zepbound's heart protection data is still being gathered, with major trial results expected soon.
GLP-1Jun 4, 2026
Retatrutide and tirzepatide both belong to the new generation of incretin-based weight loss drugs, but they work through different receptor combinations. Tirzepatide (sold as Zepbound for weight management and Mounjaro for type 2 diabetes) is FDA-approved and available now. Retatrutide is still in phase 3 clinical trials and is not yet approved for any use. Here is what the published research shows about how they compare.
GLP-1Jun 4, 2026
Retatrutide is a triple-receptor agonist (GLP-1, GIP, and glucagon) being developed by Eli Lilly for obesity and type 2 diabetes. It is not yet FDA-approved, but phase 2 trial data give a detailed picture of its side effect profile. If you are exploring GLP-1 medications that are available today, Zepbound (tirzepatide) is the closest approved option.
GLP-1Jun 1, 2026
After 176 weeks on tirzepatide, the largest obesity trial reported "no new safety signals." That's the headline from the 3-year SURMOUNT-1 follow-up of 2,539 adults with obesity, in which the 15 mg dose produced a 19.7% weight loss with the same gastrointestinal-dominated side-effect pattern visible in year one.
That's reassuring, but it doesn't answer the harder questions. Are the cardiovascular signals from the SURPASS program holding up, what does the lean-mass loss mean over years, and what happens when you stop?
Long-term safety for tirzepatide rests on three pillars: the SURPASS trials in type 2 diabetes (up to 104 weeks), the SURMOUNT trials in obesity (up to 176 weeks), and pharmacovigilance databases tracking real-world reports. Together they paint a consistent picture, with a few areas worth watching.
GLP-1May 31, 2026
Tirzepatide has generated enormous interest as a weight loss medication, and Eli Lilly has confirmed work on an oral tablet formulation. But here's what you should know: every clinical trial result published so far comes from the injectable version. No oral tirzepatide tablet has been tested in humans in any published study. This article covers what the injectable data actually shows, because that's the evidence any future oral version will be measured against. If you're considering tirzepatide for weight management, Zepbound is the FDA-approved injectable option available today.
Cardiovascular HealthMay 30, 2026
People taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, and half of them lost more than 15%. That kind of result used to require surgery. Now it comes in a weekly injection, and a pill version is catching up. GLP-1 medications have become the most talked-about drug class in a generation, but the clinical data behind them goes far deeper than weight loss alone.
These drugs were originally developed for type 2 diabetes. Along the way, researchers discovered they also reduce heart attacks, strokes, and even <>. A meta-analysis pooling data from over 60,000 patients found that GLP-1 medications cut major cardiovascular events by 14% and all-cause mortality by 12%. That's a rare combination: a drug class that helps people lose weight and live longer.
Weight LossMay 30, 2026
If you have obstructive sleep apnea (OSA) and you're carrying extra weight, you've probably heard the standard advice: lose weight and it'll get better. Easier said than done. So when a drug like Zepbound (tirzepatide) comes along and helps people lose significant weight, a natural question follows: could it actually improve your sleep apnea too?
The short answer is yes, it can make a meaningful difference. Multiple clinical analyses published in 2025 consistently show that GLP-1/GIP drugs like tirzepatide reduce the number of times your breathing stops or gets dangerously shallow each hour while you sleep. But before you start thinking you can toss your CPAP machine, there are some important caveats. This article breaks down how much improvement you can realistically expect and whether these medications could be right for your situation.
GLP-1May 30, 2026
In a head-to-head trial of 338 adults with obesity, weekly semaglutide reduced body weight by about 16% while daily liraglutide reached just 6% over the same 68 weeks. That gap matters. The choice of GLP-1 drug, the dose, and how long you stay on it collectively determine whether you lose a modest amount of weight or a quarter of your starting body mass.
GLP-1 receptor agonists have become the most effective non-surgical weight loss treatments ever tested in large trials. But the category includes several different drugs with meaningfully different results, and the details determine what you can realistically expect.
GLP-1May 30, 2026
The FDA has approved tirzepatide in six doses (2.5, 5, 7.5, 10, 12.5, and 15 mg), and not a single one is a tablet. Tirzepatide, sold under the brand names Mounjaro and Zepbound, is only approved as a once-weekly subcutaneous injection in prefilled pens or vials.
That hasn't stopped a parallel market from popping up. Compounding pharmacies have started offering "tirzepatide tablets" in sublingual and orally disintegrating forms, pitched as a needle-free alternative. These versions are not FDA-approved, have not been tested in clinical trials, and their safety and effectiveness are largely unknown.
If you're looking at tablet options because you don't want to inject, the practical question is what your real choices are. The short answer: stick with the FDA-approved injection, wait for a different oral drug that's coming through trials, or accept the unknowns of a compounded sublingual. The trade-offs differ a lot.
GLP-1May 28, 2026
In the only head-to-head trial that pitted Wegovy directly against Saxenda, patients on Wegovy lost 15.8% of their starting weight after 68 weeks. Patients on Saxenda lost 6.4%.
That gap is roughly two-and-a-half times more weight loss with the once-weekly drug than with the once-daily one. And it shows up in nearly every other measure researchers tracked.
The two drugs are often discussed in the same breath because they belong to the same family. Both are GLP-1 receptor agonists, made by the same company (Novo Nordisk), both injected, both FDA-approved for chronic weight management. But the trial data tell a clearer story than the marketing usually suggests, and the practical differences go beyond how often you stick yourself with a needle.
GLP-1May 28, 2026
At Mounjaro's highest approved dose, 15 milligrams once weekly, people with obesity lost roughly 21% of their starting body weight over 72 weeks, compared with about 3% on placebo. That kind of effect was unprecedented for a single weekly injection.
But "highest" and "best" aren't the same thing. The 15 mg dose also produces the most nausea, the most vomiting, and the highest rate of patients quitting the drug. The question of whether you should aim for 15 mg, or stop somewhere short of it, depends on what the drug is doing for you and how well your stomach is tolerating each step up.
DiabetesMay 27, 2026
Bydureon (exenatide extended-release) can drop HbA1c by roughly 1.3 to 1.6 percentage points with a single weekly injection. That's a meaningful reduction for adults with type 2 diabetes who aren't getting enough from diet, exercise, and oral medications. But here's the tension worth understanding: head-to-head data show it's slightly less potent on both blood sugar and weight than liraglutide or semaglutide, two GLP-1 receptor agonists that now dominate the conversation.
So where does that leave Bydureon? Still effective, still convenient, but no longer the frontrunner. Whether it makes sense for you depends on what you're prioritizing and what trade-offs you're willing to accept.
Metabolic HealthMay 26, 2026
In the only randomized trial that put tirzepatide directly against semaglutide for weight loss, people on tirzepatide lost an average of 20.2% of their starting weight. People on semaglutide lost 13.7%. The 6.5-percentage-point gap held across nearly every secondary outcome the trial measured.
That difference matters because the choice between these two drugs is rarely about whether they work. Both work. The question is how much extra benefit tirzepatide buys, what it costs in side effects, and whether semaglutide's longer track record on heart outcomes outweighs the smaller weight number.
GLP-1May 26, 2026
In the largest tirzepatide weight-loss trial, the average person on the highest dose lost 20.9% of their body weight at 72 weeks, with more than half of the 15 mg group dropping at least 20%. That's the headline number people quote. The more useful question is when those changes show up, what they look like along the way, and what happens after.
The "before and after" picture isn't a single before and a single after. It's a curve that starts slowly during dose escalation, accelerates through months three and four, plateaus around the year mark, and reverses sharply if the drug is stopped. If you're considering tirzepatide or already on it, the time-anchored numbers below tell you what to expect.
GLP-1May 24, 2026
Even 5 mg of tirzepatide once a week cut body weight by 15% over 72 weeks in a 2,539-person trial of adults with obesity, with 85% of people losing at least 5% of their starting weight. That dose is already on the low end of what the manufacturer studied. Anything below 5 mg as a long-term maintenance dose has almost no published outcome data.
That gap is where "microdose tirzepatide" lives. The phrase usually refers to compounded or off-label dosing schedules that sit below 5 mg per week, sometimes at 2.5 mg or even 1 mg, marketed as a way to capture the appetite suppression and modest weight loss without the gastrointestinal side effects that hit hardest at higher doses.
The pitch is appealing. The evidence base behind it is much thinner than the marketing suggests.
DiabetesMay 23, 2026
A single patch the size of a postage stamp delivered semaglutide for an entire month in animal studies, mimicking four weekly injections from one 2×2 cm application. That is genuinely exciting. It is also, for now, entirely experimental. No GLP-1 patch is approved or commercially available for diabetes or obesity. Every current GLP-1 receptor agonist, including semaglutide, liraglutide, dulaglutide, and tirzepatide, reaches patients through injections or, in the case of oral semaglutide, a daily pill.
So if you have seen headlines about GLP-1 patches and wondered whether you should ask your doctor about one, the honest answer is: not yet. But the research pipeline is worth understanding, because it signals where treatment is headed.
